Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study

Eribulin is a chemotherapeutic agent used for advanced breast cancer, but there are some reports of eribulin-induced lung injuries. Three of our patients experienced eribulin-related lung injuries. Radiology revealed organizing pneumonia in two cases and diffuse ground-glass shadows indicative of hy...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 59; no. 4; pp. 563 - 567
Main Authors Murakami, Manabu, Kanemura, Hiroaki, Tomishima, Yutaka, Nakano, Eriko, Tamura, Tomohide
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society of Internal Medicine 15.02.2020
Japan Science and Technology Agency
Subjects
Alveolitis
Antineoplastic drugs
Antitumor agents
Breast cancer
Case Report
eribulin
Hypersensitivity
Internal medicine
interstitial pneumonia
Lungs
Pneumonia
Pneumonitis
breast cancer
eribulin
interstitial pneumonia
Online AccessGet full text

Cover

More Information
Summary:Eribulin is a chemotherapeutic agent used for advanced breast cancer, but there are some reports of eribulin-induced lung injuries. Three of our patients experienced eribulin-related lung injuries. Radiology revealed organizing pneumonia in two cases and diffuse ground-glass shadows indicative of hypersensitivity pneumonitis in the third. A retrospective survey of patients treated with eribulin at our hospital identified no other cases of eribulin-induced lung injuries. Overall, drug-related lung injuries occurred in 2.8% of our eribulin-treated patients, which is similar to the rates reported for other anticancer drugs. The findings from these three cases provide guidance for the safe use of eribulin.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Correspondence to Dr.　Hiroaki Kanemura, whitetigerblink@gmail.com
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.2779-19